Novo Nordisk said Tuesday it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%, becoming the latest drugmaker to reduce the cost of the critical ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

A recent Scientific Reports study explored the association between dietary insulin index (DII) and dietary insulin load (DIL) with metabolic healthy (MH) status and the serum levels of brain-derived ...

Novo Nordisk will lower the U.S. list price of some of its insulin products by up to 75%, the Danish drugmaker said Tuesday. The change — which will take effect on Jan. 1, 2024 — follows a similar ...

AACE, ACE Statement on SGLT-2 Inhibitors and DKA Association The AACE and ACE issue a position statement regarding the possible increased risk of diabetic ketoacidosis among patients taking SGLT-2 ...

Nov 9 (Reuters) - UnitedHealth's (UNH.N), opens new tab pharmacy benefit manager unit said on Thursday it was adding eight insulin products to its reimbursement list that would limit out-of-pocket ...

Intensive Insulin Therapy in Critically Ill Patients The author in his commentary on this important study advises against intensive insulin treatment to strictly control blood glucose in critically ...